ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
Personalis will host a webinar call on June 19th, 2024 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time to present ASCO highlights from the conference
Earlier and more sensitive detection of recurrence in early-stage breast cancer
Breast cancer is currently the most common cancer in the
Breast cancer results were presented in an oral presentation by Dr. Isaac Garcia-Murillas and come from a team at the Institute of Cancer Research,
- NeXT Personal’s Ultra-sensitive range enabled earlier detection of recurrence, with a median ~15-month lead time over imaging detection
-
100% of patients that recurred were detected with NeXT Personal and100% of patients that were ctDNA negative on longitudinal testing were cancer-free -
NeXT Personal enabled detection of very low traces of cancer, with ~
39% of all detections falling in the ultra-sensitive range below 100 PPM (below0.01% of ctDNA) - NeXT Personal enabled substantially better sensitivity and lead times compared to other MRD assays on the same patient cohort
Dr. Garcia-Murillas noted, “NeXT Personal demonstrated the best MRD performance we have seen in this study cohort. With the ultra-sensitive performance of NeXT Personal, we see strong opportunities to impact breast cancer care and management, especially for the escalation and de-escalation of treatment.”
Additional breast cancer results presented at ASCO include a poster presentation by Dr. Adrienne Waks at the Dana Farber Cancer Institute using NeXT Personal to assess neoadjuvant therapy response in the DAPHNe HER2+ breast cancer trial. In this study, NeXT Personal demonstrated high baseline sensitivity (
Strong performance in immunotherapy monitoring
Several hundred thousand cancer patients are put on immunotherapy treatment annually. While over
An oral presentation showed the importance of NeXT Personal’s use for immunotherapy monitoring. Dr. Rodrigo Toledo at the Vall d'Hebron Institute of Oncology (VHIO) presented data in an oral presentation that demonstrated that the baseline levels and the changes in levels of ctDNA detected by NeXT Personal are highly predictive of therapy response and clinical outcomes for late-stage cancer patients receiving immunotherapy. This includes the finding that patients who had a significant decrease in ctDNA levels from baseline to the third cycle of immunotherapy had overall survival that was more than two times longer than those who did not. They also demonstrated that NeXT Personal had an average lead time for detecting progression of 81 days over imaging.
The VHIO data is a broad study that included patients across 18 different solid tumor types. “The changes in ctDNA levels elucidated by the NeXT Personal test can dramatically enhance our ability to understand if late-stage cancer patients are responding to their therapy. This is critical to optimally managing immunotherapy and other treatments for these very sick patients,” said Dr.
Additional results presented at ASCO include a poster presentation by Professor Andy Nixon at the Duke Cancer Institute in late-stage esophagogastric cancer that received immunotherapy in combination with chemotherapy as part of the KeyLargo trial. In this study, Dr. Nixon found that ctDNA levels were demonstrated to be highly prognostic for therapy response. In late-stage cancer patients, ctDNA levels can be very low with ~
“With the addition of the ASCO data, we now have presented data across lung cancer, breast cancer, and patients on immunotherapy that consistently highlight the importance of an ultra-sensitive MRD platform like NeXT Personal to detect recurrence earlier, monitor therapy response, and more accurately predict clinical outcomes for cancer patients,” said Dr. Richard Chen, Chief Medical Officer and EVP of R&D at Personalis. “We also expect the strong performance in these studies will help drive clinical adoption and reimbursement of NeXT Personal.”
Personalis will host a webinar call on June 19th, 2024 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time to present ASCO highlights from the conference.
Webcast and Conference Call Information
To receive the dial-in instructions, please email investors@personalis.com.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are “forward-looking statements” within the meaning of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604313776/en/
Investors:
Caroline Corner
investors@personalis.com
415-202-5678
Media:
pr@personalis.com
Source: Personalis, Inc.